PubMed HealthSearch

PubMed · 8361042

[Immunoassay].

Abstract

Since the advent of radioimmunoassay in 1959, the immunoassay technology has developed enormously as a very sensitive assay system suitable for wide range of analytes of clinical interest. Current popularity of the noncompetitive principle is attributable to its higher sensitivity, wide dynamic range and shorter incubation time. Recent innovation includes time-resolved fluorescent immunoassay designed to eliminate non-specific fluorescence, amplified enzyme-linked immunoassay and enhanced chemiluminescent immunoassay for ultra-sensitivity, particle counting immunoassay with a high resolution power, simultaneous measurement of multiple analytes, and easy-to-perform multilayer film immunoassays. Despite these advances in the technology, there remain various assay problems such as lack of standardization in reagents, a large interlaboratory variations despite the use of same assay kits, non-linear results in diluted samples and so-called prozone phenomenon.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

K Ichihara. 1993. [Immunoassay].. https://pubmed.ncbi.nlm.nih.gov/8361042/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Advances in Single-Molecule Immunoassay: From Counting Strategies to CRISPR-Enhanced Biosensing.

Single-molecule immunoassays (SMIs) overcome the sensitivity limitations of conventional bulk measurements by enabling a paradigm shift from analog to digital signal readouts, thereby facilitating highly sensitive quantification of ultra-low-abundance biomarkers for precision diagnostics. This review provides a systematic overview of recent advances in SMI technologies and the conceptual framework underlying their evolution. First, discretization strategies for single-molecule counting are classified into hard discretization, based on physical confinement, and soft discretization, based on spatiotemporal isolation, within heterogeneous and homogeneous assay systems, respectively. The fundamental mechanisms by which these strategies mitigate diffusion limitations and enhance signal-to-noise ratios are discussed. Second, the integration of SMIs with CRISPR-based diagnostic systems (CRISPR-dx) is examined, with particular emphasis on their complementary roles in target recognition and signal amplification. Finally, recent applications of SMIs in the diagnosis of oncological, neurological, infectious, and cardiovascular diseases are summarized, along with a critical discussion of current engineering challenges and future directions toward clinical translation.

Immunoassay

Synthetic peptides for diagnostic use.

Synthetic peptides representing relevant B-cell epitopes are, potentially, ideal antigens to be used in diagnostic assays because of their superior properties with respect to quality control as compared to those of biologically derived molecules and the much higher specificity that sometimes can be obtained. It is thus not a surprise than an increasing number of synthetic peptide based diagnostic assays are being developed or already are commercially available. In this report methods to define useful synthetic peptides, and diagnostic systems that are under development or on the market are discussed.

Immunoassay